Scarica l'app Stockscreener
6.98
4.88%
0.325
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché FOLD Giù?
Forum
Previsione
Precedente Chiudi:
$6.655
Aprire:
$6.72
Volume 24 ore:
3.25M
Relative Volume:
0.67
Capitalizzazione di mercato:
$2.15B
Reddito:
$493.67M
Utile/perdita netta:
$-104.69M
Rapporto P/E:
-20.53
EPS:
-0.34
Flusso di cassa netto:
$-31.51M
1 W Prestazione:
-0.14%
1M Prestazione:
+14.61%
6M Prestazione:
-26.91%
1 anno Prestazione:
-39.72%
Intervallo 1D:
$6.705
$7.01
Intervallo di 1 settimana:
$6.595
$7.065
Portata 52W:
$5.51
$12.65
Amicus Therapeutics Inc Stock (FOLD) Company Profile
Nome
Amicus Therapeutics Inc
Settore
Industria
Telefono
(609) 662-2000
Indirizzo
47 HULFISH STREET, PRINCETON, NJ
Confronta FOLD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
FOLD
Amicus Therapeutics Inc
|
6.98 | 2.05B | 493.67M | -104.69M | -31.51M | -0.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.77 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.93 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.56 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.10 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Amicus Therapeutics Inc Stock (FOLD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-17 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-13 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-09-06 | Iniziato | Jefferies | Buy |
| 2024-05-30 | Iniziato | Wells Fargo | Overweight |
| 2024-05-14 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-12-19 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-04-13 | Ripresa | Goldman | Neutral |
| 2022-01-14 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-15 | Aggiornamento | Stifel | Hold → Buy |
| 2021-09-30 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-07-19 | Ripresa | BTIG Research | Buy |
| 2021-05-27 | Iniziato | Needham | Hold |
| 2021-05-21 | Iniziato | UBS | Buy |
| 2021-04-14 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2021-03-02 | Iniziato | Stifel | Hold |
| 2021-02-12 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-12 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-12-28 | Ripresa | Cantor Fitzgerald | Overweight |
| 2020-12-10 | Downgrade | Citigroup | Buy → Neutral |
| 2020-11-11 | Iniziato | Berenberg | Hold |
| 2020-06-17 | Iniziato | BTIG Research | Buy |
| 2020-02-04 | Ripresa | Cantor Fitzgerald | Overweight |
| 2019-11-12 | Reiterato | H.C. Wainwright | Buy |
| 2019-06-17 | Iniziato | H.C. Wainwright | Buy |
| 2019-06-05 | Reiterato | Cantor Fitzgerald | Overweight |
| 2019-04-05 | Iniziato | Janney | Buy |
| 2019-01-30 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-10-29 | Iniziato | Citigroup | Neutral |
| 2018-08-17 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2017-10-06 | Ripresa | Goldman | Neutral |
| 2017-09-13 | Reiterato | Chardan Capital Markets | Buy |
| 2017-08-10 | Reiterato | Chardan Capital Markets | Buy |
| 2017-01-24 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2016-05-18 | Iniziato | BofA/Merrill | Buy |
| 2016-04-14 | Iniziato | Robert W. Baird | Neutral |
| 2016-04-12 | Reiterato | Chardan Capital Markets | Buy |
| 2015-09-16 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2015-06-16 | Reiterato | Chardan Capital Markets | Buy |
Mostra tutto
Amicus Therapeutics Inc Borsa (FOLD) Ultime notizie
Heatmap Data Shows High Activity in Amicus Therapeutics Inc. Sector [Trade Analysis Summary]Weekly Market Pulse Updates - 선데이타임즈
Why is Amicus Therapeutics Inc. stock going downMassive Profit Potential Picks - mustnews.co.kr
Amicus Therapeutics (NASDAQ:FOLD) Trading 9.3% HigherShould You Buy? - MarketBeat
What candlestick patterns are forming on Amicus Therapeutics Inc.Daily Stock Forecast Powered by AI Tools - Newser
Can trapped investors hope for a rebound in Amicus Therapeutics Inc.Free Daily Top Performing Stock Insights - Newser
How Efficient Is Amicus Therapeutics Inc. at Controlling Operating CostsFree ROI Boosting Trade Opportunity Calendar - Newser
Published on: 2025-08-08 22:45:59 - Newser
What institutional flow reveals about Amicus Therapeutics Inc.Predictive Model for Intraday Swing Forecast - Newser
Jefferies Financial Group Inc. Invests $1.53 Million in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Wall Street Zen Upgrades Amicus Therapeutics (NASDAQ:FOLD) to Buy - MarketBeat
XTX Topco Ltd Buys 68,245 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators - Benzinga
Amicus reiterates $1B sales target for Galafold and Pombiliti/Opfolda by 2028 amid global expansion and Phase III pipeline progress - MSN
Earnings Estimates Moving Higher for Amicus Therapeutics (FOLD): Time to Buy? - Yahoo Finance
Does Amicus Therapeutics (FOLD) Have the Potential to Rally 138.21% as Wall Street Analysts Expect? - sharewise.com
Assetmark Inc. Lowers Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Upgraded at Wall Street Zen - Defense World
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Position Reduced by Y Intercept Hong Kong Ltd - MarketBeat
Amicus Therapeutics Inc. Rebound Backed by Sentiment ShiftFundamental + Technical Hybrid Stock Tips Shared - metal.it
Universal Beteiligungs und Servicegesellschaft mbH Takes Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Envestnet Asset Management Inc. Lowers Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Assetmark Inc. Trims Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World
XTX Topco Ltd Has $871,000 Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World
Amicus Therapeutics Inc (FOLD) Q2 2025 Earnings Call Highlights: Sustained Revenue Growth ... By GuruFocus - Investing.com Canada
What are the latest earnings results for Amicus Therapeutics Inc.Invest in stocks with strong fundamentals - Jammu Links News
Why is Amicus Therapeutics Inc. stock attracting strong analyst attentionUnlock powerful portfolio management tools - Jammu Links News
What analysts say about Amicus Therapeutics Inc. stockFree Real-Time Stock Data - Jammu Links News
What catalysts could drive Amicus Therapeutics Inc. stock higher in 2025Phenomenal trading returns - Jammu Links News
When is Amicus Therapeutics Inc. stock expected to show significant growthDiscover stocks with massive upside potential - Jammu Links News
What are the technical indicators suggesting about Amicus Therapeutics Inc.Get daily expert analysis on top stocks - Jammu Links News
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Just Released Its Second-Quarter Earnings: Here's What Analysts Think - Yahoo Finance
What drives Amicus Therapeutics Inc. stock priceMaximize your portfolio’s growth with expert tips - Jammu Links News
How does Amicus Therapeutics Inc. compare to its industry peersExceptional market performance - Jammu Links News
What analysts say about Amicus Therapeutics Inc. stock outlookIntraday Price Forecast Using Volume Models - Newser
Should I hold or sell Amicus Therapeutics Inc. stock in 2025Unlock exclusive stock market insights - Jammu Links News
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
Is it the right time to buy Amicus Therapeutics Inc. stockBuild wealth steadily with proven investment techniques - Jammu Links News
FOLD Q2 Earnings Miss Mark, Revenues Beat on Higher Product Sales - MSN
Amicus Therapeutics Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Mesirow Financial Investment Management Inc. Decreases Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World
Victory Capital Management Inc. Purchases 82,691 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics' Q2 Performance: A Glimpse into Rare Disease Growth and Strategic Risks - AInvest
Amicus Therapeutics Surpasses $1B Target Revenues with DMX-200 License Agreement - AInvest
Amicus Therapeutics: Going Beyond $1B Target Revenues Of Lead Products With Licensed DMX-200 - Seeking Alpha
FOLD Q2 Earnings Miss Mark, Revenues Beat On Higher Product Sales - Barchart.com
Amicus Therapeutics (FOLD) Misses Q2 Earnings Estimates - MSN
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q2 2025 Earnings Call Transcript - Insider Monkey
What are analysts’ price targets for Amicus Therapeutics Inc. in the next 12 monthsDaily Trading Picks With High Returns - Jammu Links News
Envestnet Asset Management Inc. Has $1.52 Million Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World
Amicus Therapeutics: Q2 Earnings Snapshot - Greenwich Time
Amicus Therapeutics Inc Azioni (FOLD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.91%
3.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):